Preclinical studies testing the efficacy of human DEC therapy confirmed a long-term increase in dystrophin expression with improved muscle function and reduced pathological changes in the skeletal muscles following the intraosseous administration of DEC cells to the mdx/scid mouse model of DMD [30]. This evidence concerns the gene DMD and Duchenne muscular dystrophy.